Researchers at Fuwai Hospital conducted a retrospective study to evaluate the performance of Keya Medical’s deep learning-based CT-FFR product in detecting hemodynamic changes in stenosis.
Cardiovascular disease (CVD) remains the leading cause of death for women in the U.S. In honor of American Heart Month, we are highlighting the differences in women’s risk factors and primary prevention to help manage CVD in women.
On Jan. 19, two regulatory changes went into effect that intend to modernize the Physician Self-Referral Statute & the Anti-Kickback Statute, facilitating the shift to value-based care.
Keya Medical has raised $46 million in Series D funding. This funding round was led by new and existing investors, including CICC Capital, Shanghai Artificial Intelligence Investment Fund, Qianhai Gaozu Asset Management Fund, and IN CAPITAL.
EACVI Best of Imaging introduced the latest advances in cardiac CT, promoting a patient-centric, multi-modality approach to cardiovascular disease diagnosis.
Keya Medical announced that it has completed a $30 Million Series C Funding Round led by IDG Capital, with participation from investors Alwin Capital, Source Code Capital, and Tasly Group.
We have compiled a list of free virtual events hosted by professional organizations that will take place in November, covering topics in cardiology, radiology, and AI.
Examine the current challenges for coronary CTA reimbursement, the potential effects it will have on patient care, and what medical imagers can do to help improve reimbursement moving forward.
On Oct. 17 and 18, the Chengdu Science and Technology Bureau hosted the 2020 DEMO China Innovation Finals, bringing together leading companies across the country.
Dr. Kunlin Cao, President of Keya Medical R&D, participated in the Cardiovascular Disease Imaging Forum at QICCD 2020 alongside Dr. Pengfei Zhang of Shangdong University.
Dr. Kunlin Cao delivered a keynote address at the China AI in Medical Imaging Conference on Keya Medical’s experience bringing AI-powered medical imaging solutions to clinical use.
Recent research demonstrates applications for CCTA to be used as the default test for evaluating patients with stable chest pain.
On Sept. 18, Keya Medical was recognized as the winner of China’s Most Promising Company award because of its leading R&D team and innovative cardiovascular product line.